3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 30, 2016 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (NASDAQ: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm by the October 3, 2016 lead plaintiff motion deadline.

If you purchased Keryx shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Keryx made false and misleading statements and/or failed to disclose: that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in fewer production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When this information emerged to the public, the stock price of Keryx fell.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 446331